logo
Share SHARE
FONT-SIZE Plus   Neg

Outerwall Q1 Profit From Cont. Ops. Decreases; Raises 2014 Earnings Guidance

Outerwall Inc. (OUTR) reported that its first-quarter income from continuing operations decreased to $23.89 million or $0.96 per share, from $28.01 million or $0.97 per share, last year. The company said the decrease in income from continuing operations was primarily due to increased interest expense related to the $350.0 million in Senior Notes issued on March 12, 2013 and an increased loss from equity method investments.

Total earnings pers share was $0.94, compared to $0.78, previous year. Core earnings per share from continuing operations was $1.27 for the quarter.

On average, ten analysts polled by Thomson Reuters expected the company to report profit per share of $0.93 for the quarter. Analysts' estimates typically exclude special items.

Revenue increased to $600.37 million from $573.31 million. Analysts expected revenue of $586.65 million for the qauarter. The company said its year-over-year revenue growth was primarily due to the inclusion of the ecoATM business that the company acquired on July 23, 2013, and an increase in same store sales and newly installed and relocated kiosks in both the Redbox and Coinstar lines of business.

For 2014, the company expects: consolidated revenue between $2.378 billion and $2.488 billion; and core EPS from continuing operations between $6.68 and $7.18. Analysts expect the company to report 2014 profit per share of $6.20 on revenue of $2.41 billion.

For the second quarter, the company expects: consolidated revenue between $546 million and $576 million; and core EPS from continuing operations between $1.24 and $1.44. Analysts expect the company to report second-quarter profit per share of $1.54 on revenue of $591.56 million.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Credit Suisse Group AG gained around 8 percent in the morning trading in Zurich after the Swiss banking giant raised its group cost savings target, and also confirmed its medium-term 2018 pre-tax income target. It is almost the end of the year. With the exception of a few, many of the biotech stocks, like the following, on which investors had bet big this year have served up only heartbreak. Now, let's take a look at some of the pending clinical trial catalysts of this month, which will make it a December to remember. Fast food major McDonald's is investing in $12,000 espresso machines for all of its U.S. restaurants, with a view to challenge Starbucks and Dunkin' Donuts in the coffee business, Bloomberg reported. Aiming to attract more customers, the company plans to reintroduce its coffee shop McCafe in 2017..
comments powered by Disqus
Follow RTT